A Phase 3 interventional study of LMT (atorvastatin, simvastatin, or rosuvastatin) and alirocumab in Heterozygous Familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2012, is one of 14 in phase 3, and was the 16th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Australia and 17 more countries
Ages 6–17
Novartis Pharmaceuticals · Sites in Netherlands, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 20 more countries
Ages 6–11
Verve Therapeutics, Inc. · Sites in Netherlands, United States, Australia and 3 more countries
Ages 18–70
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 23 more countries
Ages 2–100
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 17 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 153 across the 33 interventional studies, 29 across the 2 observational. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 35 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 3 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study alirocumab (REGN727/SAR236553) in patients with Heterozygous Familial Hypercholesterolemia (heFH) who are not adequately controlled with their Lipid-Modifying Therapy (LMT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with heFH* who are not adequately controlled** with a maximally-tolerated daily dose*** of statin with or without other LMT, at a stable dose prior to the screening visit (week -2).
*Diagnosis of heFH must be made either by genotyping or by clinical criteria. For those patients not genotyped, the clinical diagnosis may be based on either the Simon Broome criteria for definite FH (Appendix 1) or the WHO/Dutch Lipid Network criteria with a score of >8 points (Appendix 2).
** "Not adequately controlled" is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) at the screening visit (week -2) in patients with a history of documented CVD (Appendix 3), or LDL-C ≥100 mg/dL (2.59 mmol/L) at the screening visit (week -2) in patients without a history of documented CVD.
*** "Maximally-tolerated dose" is defined as (any of the following are acceptable):
Note: Patients who are not able to be on any of the above statin doses should be treated with the dose of daily atorvastatin, rosuvastatin, or simvastatin which is considered appropriate for the patient, according to the investigator's judgment. Some examples of acceptable reasons for a patient taking a lower statin dose include, but are not limited to: adverse effects on higher doses, advanced age, low , regional practices, local prescribing information, concomitant medications, co-morbid conditions such as impaired glucose tolerance/impaired fasting glucose. The reason(s) will be documented in the case report form (CRF).
Exclusion Criteria:
(The inclusion/exclusion criteria provided above is not intended to contain all considerations relevant to a participant's potential participation in this clinical trial).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
Drug: LMT (atorvastatin, simvastatin, or rosuvastatin) · Drug: alirocumab
Placebo matched to alirocumab SC injection for 78-week treatment duration.
Drug: Placebo
Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Also known as: REGN727, SAR236553
Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted Least- squares (LS) means and standard errors at Week 24 were obtained from a mixed -effect model with repeated measures (MMRM) to account for missing data. All available post -baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment (ITT analysis).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post baseline data from Week 4 to Week 52 regardless of status on- or off treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off treatment (ITT analysis).
Time frame: From Baseline to Week 52
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 52
Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).
Time frame: Up to week 52
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 52
Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis
Adjusted percentages at Week 52 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).
Time frame: Up to Week 52
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
The study was conducted at 26 sites in 4 countries. Overall, 322 participants were screened between 28 Nov 2012 and 26 Apr 2013, 73 of whom were screen failures.
| Milestone | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Started | 167 | 82 |
| Treated | 167 | 81 |
| Completed | 0 | 0 |
| Not completed | 167 | 82 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Poor compliance to protocol | 2 | 1 |
| Withdrew: Other | 3 | 1 |
| Withdrew: Related to imp administration | 1 | 0 |
| Withdrew: Treatment ongoing | 156 | 78 |
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted Least- squares (LS) means and standard errors at Week 24 were obtained from a mixed -effect model with repeated measures (MMRM) to account for missing data. All available post -baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis | -48.7 ± 1.9 | 2.8 ± 2.8 |
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | -49.4 ± 1.9 | 2.7 ± 2.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment (ITT analysis).
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | -43.8 ± 1.8 | 4.6 ± 2.6 |
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis | -44.2 ± 1.8 | 4.6 ± 2.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | -42.8 ± 1.4 | -3.5 ± 2 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis | -43.2 ± 1.4 | -3.5 ± 2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | -42.6 ± 1.8 | 3.1 ± 2.5 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis | -43.2 ± 1.7 | 3.1 ± 2.5 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | -30.6 ± 1.4 | 2.1 ± 1.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | -35.4 ± 1.4 | -0.9 ± 2 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | -37.9 ± 1.7 | 4.1 ± 2.4 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post baseline data from Week 4 to Week 52 regardless of status on- or off treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | -26.6 ± 1.3 | 3.4 ± 1.9 |
Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off treatment (ITT analysis).
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis | -50.3 ± 2.3 | 8.4 ± 3.3 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis | 81.4 | 11.3 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).
| percentage of participants | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis | 82.1 | 11.6 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 68.2 | 1.2 |
Adjusted percentages at Week 52 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).
| percentage of participants | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis | 68.8 | 1.3 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis | -30.3 ± 1.8 | -10 ± 2.5 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | 6.0 ± 1.2 | -0.8 ± 1.6 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | -10.4 ± 2 | 0.5 ± 2.8 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis | 2.8 ± 0.9 | -1.6 ± 1.3 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | -24.7 ± 1.7 | -5.6 ± 2.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | 6.0 ± 1.0 | -0.8 ± 1.6 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | -8.1 ± 2.2 | 0.6 ± 3.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis | 0.4 ± 0.9 | -1.9 ± 1.3 |
Collected over From Baseline up to Week 78. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alirocumab 75 mg/up to 150 mg | — | 10/167 (6%) | 65/167 (38.9%) |
| Placebo | — | 7/81 (8.6%) | 35/81 (43.2%) |
| Event | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| Acute coronary syndromeCardiac disorders | 0/167 | 1/81 |
| Angina unstableCardiac disorders | 0/167 | 1/81 |
| Cardiogenic shockCardiac disorders | 0/167 | 1/81 |
| Myocardial infarctionCardiac disorders | 0/167 | 1/81 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/167 | 1/81 |
| Non-Cardiac chest painGeneral disorders | 0/167 | 1/81 |
| EndocarditisInfections and infestations | 0/167 | 1/81 |
| Lower respiratory tract infectionInfections and infestations | 0/167 | 1/81 |
| Viral infectionInfections and infestations | 0/167 | 1/81 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/167 | 1/81 |
| Event | Alirocumab 75 mg/up to 150 mg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/167 | 16/81 |
| InfluenzaInfections and infestations | 24/167 | 6/81 |
| Injection site reactionGeneral disorders | 18/167 | 6/81 |
| HeadacheNervous system disorders | 14/167 | 7/81 |
| MyalgiaMusculoskeletal and connective tissue disorders | 10/167 | 5/81 |
| DiarrhoeaGastrointestinal disorders | 9/167 | 1/81 |
| Age, Continuous(years) | Alirocumab 75 mg/up to 150 mg | Placebo | Total |
|---|---|---|---|
| Mean | 53.2 ± 12.93 | 53.2 ± 12.55 | 53.2 ± 12.8 |
| Sex: Female, Male(Participants) | Alirocumab 75 mg/up to 150 mg | Placebo | Total |
|---|---|---|---|
| Female | 81 | 37 | 118 |
| Male | 86 | 45 | 131 |
| Calculated LDL-C in mmol/L(mmol/L) | Alirocumab 75 mg/up to 150 mg | Placebo | Total |
|---|---|---|---|
| Mean | 3.485 ± 1.065 | 3.471 ± 1.071 | 3.480 ± 1.065 |
| Calculated LDL-C in mg/dL(mg/dL) | Alirocumab 75 mg/up to 150 mg | Placebo | Total |
|---|---|---|---|
| Mean | 134.6 ± 41.1 | 134.0 ± 41.4 | 134.4 ± 41.1 |
The record gives a start of Dec 2012, a primary completion of May 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab
Hyperlipoproteinemia Type II →